Another study of approximately 5000 patients with hypertension and type 2 diabetes demonstrated reductions in mean plasma glucose in those treated with nebivolol as monotherapy (21.4%), although 48.4% were also being treated with an ACE inhibitor or angiotensin receptor blocker (ARB) [38–41]. The gene discussed is ACE; the disease is type 2 diabetes mellitus.